Neurocrine Biosciences, based in San Diego, develops pharmaceuticals for neurological disorders and employs 1,448 people. Its FDA-approved products include INGREZZA and Orilissa, with a strong clinical development pipeline.
Jude Onyia sold 20,362 shares of NBIX on 2 July at $130.13 per share, worth a total of $2.6M. They now own 18,289 NBIX shares, or a 53% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
